1. Home
  2. ZYME vs SHEN Comparison

ZYME vs SHEN Comparison

Compare ZYME & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • SHEN
  • Stock Information
  • Founded
  • ZYME 2003
  • SHEN 1902
  • Country
  • ZYME United States
  • SHEN United States
  • Employees
  • ZYME N/A
  • SHEN N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • SHEN Telecommunications Equipment
  • Sector
  • ZYME Health Care
  • SHEN Telecommunications
  • Exchange
  • ZYME Nasdaq
  • SHEN Nasdaq
  • Market Cap
  • ZYME 751.6M
  • SHEN 769.1M
  • IPO Year
  • ZYME 2017
  • SHEN N/A
  • Fundamental
  • Price
  • ZYME $15.39
  • SHEN $12.93
  • Analyst Decision
  • ZYME Buy
  • SHEN Strong Buy
  • Analyst Count
  • ZYME 5
  • SHEN 1
  • Target Price
  • ZYME $19.00
  • SHEN $26.00
  • AVG Volume (30 Days)
  • ZYME 572.6K
  • SHEN 257.3K
  • Earning Date
  • ZYME 10-31-2024
  • SHEN 11-07-2024
  • Dividend Yield
  • ZYME N/A
  • SHEN 0.77%
  • EPS Growth
  • ZYME N/A
  • SHEN 5657.38
  • EPS
  • ZYME N/A
  • SHEN 3.75
  • Revenue
  • ZYME $62,199,000.00
  • SHEN $328,807,000.00
  • Revenue This Year
  • ZYME $30.09
  • SHEN $19.26
  • Revenue Next Year
  • ZYME N/A
  • SHEN $20.54
  • P/E Ratio
  • ZYME N/A
  • SHEN $3.57
  • Revenue Growth
  • ZYME N/A
  • SHEN 21.23
  • 52 Week Low
  • ZYME $7.80
  • SHEN $11.87
  • 52 Week High
  • ZYME $17.70
  • SHEN $24.13
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 55.74
  • SHEN 42.10
  • Support Level
  • ZYME $12.39
  • SHEN $12.37
  • Resistance Level
  • ZYME $17.70
  • SHEN $13.16
  • Average True Range (ATR)
  • ZYME 0.84
  • SHEN 0.80
  • MACD
  • ZYME 0.10
  • SHEN -0.14
  • Stochastic Oscillator
  • ZYME 56.50
  • SHEN 20.80

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through two business units: tower and broadband. The tower segment leases company-owned cell tower spaces to other wireless communication providers, while the broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

Share on Social Networks: